CLINICAL NEUROPATHOLOGY is a vital scholarly journal published by DUSTRI-VERLAG DR KARL FEISTLE, specializing in the domains of neurology, pathology, and their clinical applications. Established in 1982 and spanning through to its projected completion in 2024, this journal disseminates high-quality research that significantly contributes to the understanding of neurological disorders and their pathological underpinnings. While the journal currently operates under a traditional access model, its commitment to rigorous peer review ensures the publication of impactful findings, strengthening its foothold in the field, as evidenced by its Q3 quartile rankings in several categories, including Medicine (miscellaneous), Neurology, and Pathology and Forensic Medicine. Those engaged in clinical research and practice will find CLINICAL NEUROPATHOLOGY to be an essential resource for the latest advancements, trends, and discussions that shape the future of neurological pathology.

Welcome to Molecular Neurobiology, the premier journal dedicated to the exploration of the molecular mechanisms underlying nervous system function and pathophysiology. Published by Springer, this journal provides an essential platform for disseminating high-quality research in the rapidly evolving fields of Cellular and Molecular Neuroscience and Neurology, boasting an impressive impact factor that reflects its esteemed position within the academic community. With its ranking in the Q1 and Q2 quartiles for various neuroscience categories, Molecular Neurobiology stands at the forefront of groundbreaking discoveries, showcasing innovative studies that bridge basic science and clinical application. Researchers and professionals are invited to contribute to its rich portfolio, which spans from fundamental insights into cellular processes to advanced therapeutic strategies. Although Molecular Neurobiology does not operate as an Open Access journal, its influential body of work remains accessible through institutional and personal subscriptions. As we converge from 1987 to 2024, we continue to aim for excellence, seeking to catalyze progress in understanding neurological diseases and enhance the scientific dialogue within the neuroscience community.

Cell Death & Disease, published by SpringerNature, is a premier open-access journal dedicated to disseminating high-quality research on the mechanisms and implications of cell death, disease pathology, and therapeutic responses. Since its inception in 2010, the journal has quickly established itself within the top tier of academic publishing, achieving a notable impact factor and earning Q1 rankings in several critical categories including Cancer Research, Cell Biology, Cellular and Molecular Neuroscience, Immunology, and Medicine (miscellaneous). With its commitment to open access, Cell Death & Disease ensures that groundbreaking research is available to a global audience, fostering collaboration and advancing knowledge across disciplines. Residing at the forefront of crucial scientific discourse, this journal not only attracts submissions from leading researchers but also significantly influences the fields of molecular biology, immunology, and neurology. By bridging the gap between basic science and clinical applications, it provides vital insights for professionals, academicians, and students alike.

Nature Reviews Neurology, published by NATURE PORTFOLIO, stands as a leading scholarly journal dedicated to the field of neurology and neuroscience. With an impressive impact factor and a prestigious Q1 categorization in both Cellular and Molecular Neuroscience and Clinical Neurology, this journal provides cutting-edge reviews and insights into the latest research developments, trends, and clinical practices. Based in the United Kingdom and accessible to a global audience, Nature Reviews Neurology aims to foster knowledge dissemination and interdisciplinary collaboration among researchers, healthcare professionals, and educators. With an influential Scopus ranking, it remains a pivotal resource for those seeking to deepen their understanding of neurological disorders and therapies while remaining at the forefront of academic discourse and innovation in the field.

MOLECULAR THERAPY, published by CELL PRESS, is a distinguished journal in the field of molecular biology and therapy, renowned for its significant contributions to drug discovery, genetics, and pharmacology since its inception in 2000. This prestigious journal, which holds a commendable position in the Q1 category across multiple disciplines including Drug Discovery, Molecular Medicine, and Molecular Biology, facilitates cutting-edge research and innovative therapies that aim to improve patient outcomes. With an impressive Scopus ranking that places it among the top journals in its field—such as rank #6 in Drug Discovery and #8 in Pharmacology—MOLECULAR THERAPY is crucial for researchers, professionals, and students seeking to advance their understanding and application of molecular techniques. The journal welcomes high-quality submissions that explore the therapeutic potential of molecular mechanisms, fostering a collaborative spirit within the scientific community to push the boundaries of modern medicine.

Acta Neuropathologica Communications is a distinguished open-access journal published by BMC since 2013, focusing on the rapidly advancing fields of neurology, cellular and molecular neuroscience, and pathology. Located in the United Kingdom, this journal serves as a vital platform for researchers to disseminate significant findings that enhance our understanding of neurological disorders and their underlying mechanisms. With an impressive impact factor reflected in its Q1 ranking across multiple relevant categories, including Cellular and Molecular Neuroscience, Neurology (Clinical), and Pathology and Forensic Medicine, Acta Neuropathologica Communications stands out in the academic community for its rigorous peer-review process and commitment to high-quality research. The journal’s Scopus rankings highlight its global relevance, placing it in the top percentiles among leading research publications. Researchers, professionals, and students alike are encouraged to access and contribute to this essential resource, fostering a collaborative and informed approach to tackling the complexities of neuropathology and neuroscience.

The Annual Review of Neuroscience, published by Annual Reviews, is a premier journal that has been at the forefront of neuroscience research since its inception in 1978. With an ISSN of 0147-006X and E-ISSN 1545-4126, this leading academic journal boasts a remarkable impact factor, placing it in the prestigious Q1 category in Neuroscience (miscellaneous), with an impressive Scopus ranking of 4 out of 113 and a stellar 96th percentile in general neuroscience. Focused on publishing comprehensive and authoritative review articles, the Annual Review of Neuroscience aims to synthesize and critically evaluate the latest advances in the field, making it an indispensable resource for researchers, professionals, and students alike. While it does not offer open access, the insights and discoveries highlighted in its issues are crucial for those dedicated to understanding the complexities of the nervous system and driving forward innovative research. With a commitment to excellence and a forward-looking perspective, this journal continues to shape and influence the future of neuroscience.

Translational Neurodegeneration, an esteemed journal in the field of neuroscience, is published by BMC and has been an open access platform since 2012, delivering high-quality research from its base in the United Kingdom. With an impressive impact factor reflecting its significant contributions, this journal focuses on critical advancements in cellular and molecular neuroscience, cognitive neuroscience, and clinical neurology, boasting a Q1 ranking across all these categories as of 2023. Researchers and professionals benefit from its extensive reach, characterized by exceptional Scopus rankings that place it in the top percentile of its field. The journal serves as a vital resource for academics and healthcare practitioners alike, aiming to bridge the gap between laboratory discoveries and clinical applications, thereby enhancing understanding and treatment of neurodegenerative diseases. With its commitment to open access, Translational Neurodegeneration ensures that its published research is accessible to a global audience, promoting collaboration and knowledge exchange within the scientific community.

ASN Neuro is an esteemed academic journal published by Frontiers Media SA, focusing on critical advancements in the fields of neurology and neuroscience. Since its inception in 2009, it has established itself as an Open Access platform dedicated to fostering the dissemination of knowledge and research findings that address the complexities of the nervous system. With an impressive impact factor and consistently ranking in the top quartiles of its categories—Q1 in Neurology (clinical) and Q2 in Neuroscience (miscellaneous)—ASN Neuro is recognized for its high-quality publications that cater to the evolving challenges in clinical neurology and general neuroscience. Currently, it ranks 68th out of 400 journals in Clinical Neurology and 28th out of 113 in General Neuroscience, affirming its reputable position within the academic community. Researchers, professionals, and students alike are encouraged to contribute to and benefit from this impactful journal as it presents a unique opportunity to engage with cutting-edge research, innovative methodologies, and insightful reviews in the ever-evolving landscape of brain science.

Molecular Neurodegeneration is a leading journal published by BMC, dedicated to advancing the field of neurodegeneration through high-quality, open-access research. Since its inception in 2006, this peer-reviewed journal has provided a pivotal platform for the dissemination of innovative findings in the realms of Cellular and Molecular Neuroscience, Molecular Biology, and Clinical Neurology. With a stellar impact factor and listed in the prestigious Q1 category in multiple relevant categories, it ranks among the top publications in the field—specifically, it holds the #3 position in Neuroscience and #6 position in Clinical Neurology based on Scopus metrics. Researchers, professionals, and students alike will find significant value in the open access format, which fosters unrestricted sharing of knowledge, ensuring that emerging ideas in neurodegeneration reach a global audience. Based in London, United Kingdom, the journal promises a comprehensive scope that addresses critical questions in neurobiology, making it an essential resource for anyone interested in the molecular mechanisms underlying neurodegenerative diseases.